Articles tagged with Crisprs
Researchers identified a promising new strategy for reversing autism-related brain deficits by targeting a specific glycine transporter. The therapy restored NMDA receptor function in mouse models and human brain organoids, improving behavioral abnormalities such as social interaction and repetitive behaviors.
The SMArT platform achieves near-pure selection of correctly edited blood stem cells while reducing dangerous genomic alterations. The innovative strategy enables enrichment of cells with targeted integration to 100% purity.
Researchers develop irreversible CRISPR base editing system to permanently block microbial survival, reducing environmental risk and genetic instability. The technology has broad applications in industrial biotechnology and biopharmaceutical fields.
A new CRISPR protein, Cas12a2, has shown potential for killing sick cells while leaving healthy ones untouched. Researchers have tested its effectiveness in destroying cancer cells and virus-infected cells with promising results.
A new CRISPR tool has been developed to eliminate specific cells based on their RNA signature. The nuclease Cas12a2 can target any RNA sequence with high sensitivity and specificity, making it a promising approach for selectively killing cancer cells, virus-infected cells, and unmodified cells.
New technologies are shifting healthcare towards proactive care, using AI for early heart disease detection and miniaturized CRISPR-based diagnostics. These innovations enable seamless integration of existing medical screenings and provide laboratory-grade accuracy in a portable format.
Researchers at Gladstone Institutes identified hundreds of human genes influencing HIV infection and two potent antiviral proteins, PI16 and PPID. These proteins block HIV's entry into T cells or limit its ability to replicate within the cell.
Researchers used genome editing to inactivate a gene involved in anthocyanin production, resulting in increased accumulation of other flavonoids. This modification did not affect lettuce growth, suggesting a promising strategy for developing cultivars with tailored functional components.
A research team at HIRI discovered that CRISPR-Cas13 systems produce an RNA-based 'hairpin' structure to prevent the formation of waste RNAs, known as ecrRNAs. This mechanism optimizes the system's interaction and enhances its efficacy in immune defense and gene editing.
A team from The University of Osaka has identified the MIC11 gene as essential for parasite egress, disrupting the parasite life cycle. This finding could guide the development of novel treatments for parasite-borne diseases.
Researchers have discovered a smaller CRISPR enzyme, Al3Cas12f, that can efficiently edit genes in human cells. The enzyme's unique structure allows it to form a stable connection with DNA, making it a promising candidate for therapeutic genome editing.
The review emphasizes the need for robust non-clinical safety assessment to ensure CRISPR/Cas gene therapy products' safe translation. Central risks include genotoxicity and immunogenicity, mitigated by high-fidelity Cas variants and emerging delivery strategies.
Researchers at Bar-Ilan University have discovered that changing just one letter in DNA can completely alter sex development in mice. A single-letter insertion in a non-coding regulatory region caused XX mice to develop as males with testis and male genitalia.
Gladstone Institutes investigator Ryan Corces receives $750,000 to investigate unknown genetic variants contributing to Alzheimer's disease. He aims to identify new drivers and therapeutic targets using artificial intelligence and CRISPR tools.
Researchers have discovered an RNA-guided CRISPR system that can activate genes without cutting DNA, opening up new possibilities for gene regulation and therapeutic strategies. The system uses a strand of RNA as a guide to recruit the cell's transcription machinery, allowing for precise control over gene expression.
A genome-wide CRISPR/Cas9 knockout screen identified two critical host factors, SLC35A1 and LSM12, essential for BPIV3 replication. Knockout of these genes significantly inhibits viral infection, revealing novel antiviral strategies to combat Bovine Respiratory Disease Complex.
A new approach, called INSTALL, enables non-toxic DNA integration in multiple human cell types and successfully inserts large genetic payloads in mice, offering a promising solution for genetic therapies. The study's findings have the potential to broaden the applicability of genome editing therapies.
Engineers have refined a technology to edit individual genetic base pairs, reducing unintended edits and increasing safety for potential treatments. The new base editors could lead to better outcomes for some cystic fibrosis patients and more accurate models for drug testing.
Researchers used a virus-based CRISPR system to edit the gatekeeper enzyme HMGR in petunias and lettuce, unlocking natural metabolic control for enhanced aromatic compounds and health-promoting antioxidants. The result was more vigorous growth, stronger floral fragrance, and increased nutritional value.
Harlequin ichthyosis is caused by ABCA12 mutations leading to defective lipid transport and loss of skin barrier function. Management includes neonatal care, systemic retinoids, daily emollients, and keratolytics, with improved survival rates and quality of life.
A team of researchers uses CRISPR gene editing to eliminate cells with amplified oncogenes, reducing tumour growth and increasing animal survival. The study offers a promising approach for precision therapies in resistant cancers.
A field-deployable CRISPR-based biosensing platform has been developed for rapid, on-site monitoring of marine species and ecosystems, offering a sustainable solution for tracking ocean health. The technology has the potential to detect critical species, predict outbreaks, and support early warning systems for ecosystem disruptions.
Researchers at UC San Francisco have identified CUL5, a protein that tags tau for elimination, as a key player in preventing the formation of toxic tau protein clumps that can lead to dementia. The study found that neurons with more CUL5 are less vulnerable to Alzheimer's disease.
Researchers at the University of British Columbia have developed a topical CRISPR-based therapy that can correct faulty genes in human skin, potentially treating genetic skin conditions like ARCI and eczema. The treatment, using lipid nanoparticle technology, restores up to 30% of normal skin function.
Researchers at Monash University have developed an AI-powered approach to create highly accurate and specific anti-CRISPR molecules, enabling faster development of gene editing tools for various applications. This breakthrough addresses the inconsistent performance and safety risks associated with CRISPR technology.
Researchers discovered that CHD1 and MAP3K7 gene deletion improves tumor vulnerability to immunotherapy. This finding suggests new biomarkers for predicting patient response and opening up personalized cancer care. The study sheds light on why some patients are more or less likely to respond to certain types of cancer treatments.
A two-step genome editing method integrates large human genomic fragments into mice, mimicking human regulatory landscapes. This platform enables the creation of physiologically relevant humanized models for therapeutic targets and disease research.
A new diagnostic platform enables rapid and accurate detection of drug-resistant C. auris pathogens using CRISPR technology, allowing for more effective treatment and prevention of hospital outbreaks. The dSHERLOCK test can detect the presence of mutations causing antimicrobial resistance in just 40 minutes.
The CRISPR-Cas3 system has been shown to induce reliable and extensive deletions of the TTR gene in mouse models of ATTR, reducing serum TTR levels by up to 80%. This technology holds promise for treating not onlyATTR but also other incurable inherited diseases.
Researchers discovered genes that regulate fibroblast growth, which builds the scaffolding between cells. Adjusting these factors reversed age-related changes and improved health outcomes in mice. The study offers new opportunities to understand and reverse aging-related diseases.
Researchers have identified a novel CRISPR mechanism, Cas12a3, that specifically targets transfer ribonucleic acids (tRNA) in bacteria. This discovery provides new insights into the immune response of bacteria and has potential applications for molecular diagnostics and other technologies.
A CRISPR screen identified 331 essential genes for brain cell generation, including PEDS1 linked to a severe developmental disorder. The study provides a new approach to identifying genes involved in neurodevelopmental disorders like autism and offers insights into gene inheritance patterns.
Researchers at Nara Institute of Science and Technology discovered that parasitic plants recognize
Researchers have identified DNA switches that control how brain cells called astrocytes work, which are known to play a role in Alzheimer's disease. The study used CRISPRi technology and single-cell RNA sequencing to test nearly 1000 potential switches, finding that about 150 of them controlled genes implicated in Alzheimer's disease.
Scientists at Penn Vet have identified two genes, Ctnna1 and Bcl2l13, that suppress metastasis in preclinical models of colorectal cancer. These findings could lead to better treatments and therapies for patients with metastatic disease.
Researchers used CRISPR to increase fungal production efficiency and cut environmental impact by 61% without adding foreign DNA. The genetically tweaked fungus tastes like meat and is easier to digest than its naturally occurring counterpart.
Researchers found that CRISPR-Cas9 gene editing persists longer and produces more predictable results in non-dividing neurons. They also discovered new DNA repair genes that can be used to control gene editing outcomes, which could lead to safer and more effective therapies for genetic diseases.
Researchers have shown that disabling the NRF2 gene with CRISPR technology can restore drug sensitivity and slow tumor growth in lung cancer. The approach, which targets a master switch for resistance, has potential across multiple tumor types.
A recent study published in Nature Communications reveals that the mechanical properties of the developing brain play a significant role in synapse formation and electrical signal emergence. The researchers found that softer regions exhibit higher synapse densities, while stiffer regions show lower densities.
Researchers at Gladstone Institutes and UCSF have identified the genetic switches that regulate FOXP3 levels in human and mouse cells. In humans, multiple enhancers work together to keep FOXP3 active, while a repressor keeps it off in conventional T cells. This discovery has important implications for developing immune therapies.
Researchers developed a scalable method to produce human kidney organoids, combining them with pig kidneys outside the body for transplantation. The transplanted organs functioned normally and showed no signs of damage or toxicity.
Researchers at the University of Texas at Austin have developed a novel gene-editing method that can correct multiple disease-causing mutations simultaneously. This approach uses bacterial retrons to protect the microbes from viral infection and has shown promising results in correcting scoliosis-causing mutations in zebrafish embryos.
Researchers developed a new diagnostic test, CAARRD, to detect ribonucleic acid (RNA) at room temperature, increasing sensitivity and reducing complexity. The test uses special 'anti-tag' CRISPR sequences to block the activity of the Cas13a enzyme, allowing for faster and more affordable detection of viral RNAs such as HIV.
Researchers at CNIO have created a 'human repairome', a catalogue of 20,000 DNA 'scars' that reveal how genes affect DNA repair. This information can help determine the best treatment for each cancer type and overcome resistance to therapy.
The CityUHK team is developing two core therapeutic medicines using state-of-the-art DNA surgery technology to treat liver and cardiovascular genetic diseases. Their approach offers a durable and long-lasting solution, eliminating the need for repeated medications.
Researchers discovered that the functional splitting of transposon-derived RNAs drove the emergence of Type V CRISPR-Cas immunity. This innovation enabled the development of compact nucleases with flexible guide RNAs, offering design principles to create smaller and more versatile CRISPR tools.
Researchers identified genetic modifications that can improve the efficacy of chimeric antigen receptor (CAR)-T cell treatment for multiple myeloma and other cancers. The study used CRISPR screening to pinpoint genes that influenced T cell function and survival in culture and in a preclinical model of multiple myeloma.
A new high-throughput screening approach has enhanced CRISPR genome-editing efficiency by identifying promising CAST variants. The method allows for rapid optimization of these candidates, uncovering mechanistic insights that can inform further engineering and potential clinical use.
Researchers at UC San Diego have created a new genetic editing approach that uses small nuclear RNA base editing, which can modify the genetic code with greater precision and safety than CRISPR. This method has the potential to treat various diseases, including neurodegenerative, cardiovascular, and immune disorders.
Scientists at UCSF successfully used CRISPRa to increase SCN2A levels in mice with the genetic disorder, resulting in reduced seizures and improved brain function. The therapy offers hope for treating neurodevelopmental issues related to SCN2A haploinsufficiency.
Researchers at MIT have developed a new approach to gene editing that reduces errors by up to 90%, making it a safer alternative for treating genetic diseases. The technique uses modified versions of the Cas9 enzyme to target specific DNA sequences, reducing off-target effects and increasing precision.
Researchers at Stanford Medicine have created an AI-powered CRISPR tool called CRISPR-GPT, which helps scientists design and analyze gene-editing experiments. The technology aims to produce lifesaving drugs faster and expand access to gene editing for a wider range of scientists, including those with limited experience.
Researchers from Mass General Brigham developed a bespoke CRISPR-Cas9 gene-editing enzyme to correct the genetic error causing multisystemic smooth muscle dysfunction syndrome, a rare condition associated with stroke and death in childhood. The therapy extended survival four-fold in mouse models of MSMDS.
Researchers at Northwestern University have developed a new CRISPR delivery system that triples efficiency using DNA-wrapped nanoparticles, improving safety and effectiveness. The new system, called LNP-SNAs, targets specific cells and tissues, reducing toxicity and boosting gene-editing efficiency by threefold.
A key contributor is the lab of Prof. Ayal Hendel at Bar-Ilan University's Goodman Faculty of Life Sciences, focusing on evaluating CRISPR-based gene editing precision and safety. The project aims to decentralize CAR-T cell therapy production, making it available to more patients by reducing costs and increasing accessibility.
Researchers have developed a new epigenetic editing method using CRISPR technology, which can switch genes back on by removing methyl groups attached to silenced or suppressed genes. This approach shows promise for treating people with Sickle Cell-related diseases, reducing the risk of unwanted changes and potential health problems.